Premium
Pre‐treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma
Author(s) -
Reddy Jay P.,
Hernandez Mike,
Gunther Jillian R.,
Dabaja Bouthaina S.,
Martin Geoffrey V.,
Jiang Wen,
Akhtari Mani,
Allen Pamela K.,
Atkinson Bradley J.,
Smith Grace L.,
Pinnix Chelsea C.,
Milgrom Sarah A.,
Abou Yehia Zeinab,
Osborne Eleanor M.,
Oki Yasuhiro,
Lee Hun,
Hagemeister Fredrick,
Fanale Michelle A.
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15054
Subject(s) - medicine , stage (stratigraphy) , lymphocyte , multivariate analysis , univariate analysis , neutrophil to lymphocyte ratio , lymphoma , gastroenterology , platelet , oncology , biology , paleontology
Summary To determine whether pre‐treatment neutrophil/lymphocyte ( NLR ) or platelet/lymphocyte ratios ( PLR ) are predictive for progression in early‐stage classical Hodgkin lymphoma ( cHL ), we derived NLR and PLR values for 338 stage I/ II cHL patients and appropriate cut‐off point values to define progression. Two‐year freedom from progression ( FFP ) for patients with NLR ≥6·4 was 82·2% vs. 95·7% with NLR <6·4 ( P < 0·001). Similarly, 2‐year FFP was 84·3% for patients with PLR ≥266·2 vs. 96·1% with PLR <266·2 ( P = 0·003). On univariate analysis, both NLR and PLR were significantly associated with worse FFP ( P = 0·001). On multivariate analysis, PLR remained a significant, independent prognostic factor ( P < 0·001).